BackLiminatus Pharma Warrants Overview

Liminatus Pharma Warrants Total Assets

Track Liminatus Pharma Warrants's total assets ($280M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$276.34M
↓ 0.40% YoYΔ $-1.10M vs prior year quarter

Peer trimmed avg / median

Loading

Liminatus Pharma Warrants Total Assets History

Loading

Liminatus Pharma Warrants vs. peers: Total Assets Comparison

Loading

Liminatus Pharma Warrants Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Liminatus Pharma Warrants (LIMNW) FAQ

The latest total assets for LIMNW is $280M as of March 2022. That compares with $280M in the prior-year period — down 0.4% year over year. Investors often review this figure alongside Liminatus Pharma Warrants's historical trend and sector peers before judging valuation or financial health.

Over the past year, LIMNW's total assets moved from $280M to $280M — a 0.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Liminatus Pharma Warrants's operating scale or balance-sheet position.

A total assets figure of $280M for LIMNW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LIMNW's total assets ($280M), review year-over-year change from $280M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.